# The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

> **NCT00002387** · NA · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00002387
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002387, "The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*